Literature DB >> 1553795

Protection by a polyvalent vaccine against challenge infection and pyelonephritis.

D Kruze1, K Biro, K Holzbecher, M Andrial, W Bossart.   

Abstract

The protective effect of immunization with a polyvalent vaccine (SolcoUrovac) was studied in the mouse and the rat. The i.m. immunization increased the resistance of mice to challenge infection with all homologous strains of bacteria. The LD50 values for E. coli, Proteus mirabilis and Streptococcus were 3.5-4.5 times and that of Klebsiella as much as 600 times that in nonimmunized mice. Protection against challenge with heterologous E. coli was also achieved and persisted for about 20 weeks. Immunization with the vaccine also provided marked protection against pyelonephritis in rats. Kidneys with abscesses were seen only one-third as often as in controls, and the size of the individual abscesses was substantially smaller in the vaccinated animals. Based on the quantity of bacteria in the kidneys it was postulated that the vaccination increased the clearance of bacteria.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1553795     DOI: 10.1007/bf00296534

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  12 in total

1.  Effects of antibiotics and vaccination on experimental pyelonephritis.

Authors:  H M WEYRAUCH; M L ROSENBERG; A D AMAR; M REDOR
Journal:  J Urol       Date:  1957-11       Impact factor: 7.450

2.  Urinary antibody response after immunisation with a vaccine against urinary tract infection.

Authors:  D Kruze; K Holzbecher; M Andrial; W Bossart
Journal:  Urol Res       Date:  1989

3.  The Influence of Endotoxin on Resistance to Infection.

Authors:  A I Braude; J Siemienski
Journal:  Bull N Y Acad Med       Date:  1961-07

4.  Experimental pyelonephritis: a new method for inducing pyelonephritis in the rat.

Authors:  T E Miller; K B Robinson
Journal:  J Infect Dis       Date:  1973-03       Impact factor: 5.226

5.  Experimental hematogenous pyelonephritis due to Escherichia coli in rabbits: the antibody response and its protective capacity.

Authors:  B Kaijser; S Olling
Journal:  J Infect Dis       Date:  1973-07       Impact factor: 5.226

6.  Host defence against intraperitoneal Escherichia coli infections in mice.

Authors:  S Ahlstedt
Journal:  Prog Allergy       Date:  1983

7.  Experimental haematogenous pyelonephritis in mice with uropathogenic, enteropathogenic and enterotoxigenic Escherichia coli.

Authors:  K Kakar; S Sharma; P J Asnani; C K Banerjee; B K Sharma
Journal:  Antonie Van Leeuwenhoek       Date:  1986       Impact factor: 2.271

8.  Protection against ascending Escherichia coli pyelonephritis in rats and significance of local immunity.

Authors:  B Kaijser; P Larsson; S Olling
Journal:  Infect Immun       Date:  1978-04       Impact factor: 3.441

9.  Elevation of secretory IgA antibodies in the urinary tract by immunostimulation for the pre-operative treatment and post-operative prevention of urinary tract infections.

Authors:  H Rüttgers; E Grischke
Journal:  Urol Int       Date:  1987       Impact factor: 2.089

10.  Immunization against retrograde pyelonephritis. II. Prevention of retrograde Escherichia coli pyelonephritis with vaccines.

Authors:  S J Brooks; J M Lyons; A I Braude
Journal:  Am J Pathol       Date:  1974-02       Impact factor: 4.307

View more
  7 in total

1.  UTI patients have pre-existing antigen-specific antibody titers against UTI vaccine antigens.

Authors:  Christina A Sarkissian; Christopher J Alteri; Harry L T Mobley
Journal:  Vaccine       Date:  2019-07-15       Impact factor: 3.641

Review 2.  Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine.

Authors:  Ariel R Brumbaugh; Harry L T Mobley
Journal:  Expert Rev Vaccines       Date:  2012-06       Impact factor: 5.217

Review 3.  Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections.

Authors:  Valerie P O'Brien; Thomas J Hannan; Hailyn V Nielsen; Scott J Hultgren
Journal:  Microbiol Spectr       Date:  2016-02

Review 4.  Waging war against uropathogenic Escherichia coli: winning back the urinary tract.

Authors:  Kelsey E Sivick; Harry L T Mobley
Journal:  Infect Immun       Date:  2009-11-16       Impact factor: 3.441

5.  Development of a Vaccine against Escherichia coli Urinary Tract Infections.

Authors:  Harry L T Mobley; Christopher J Alteri
Journal:  Pathogens       Date:  2015-12-31

6.  Rapid Bladder Interleukin-10 Synthesis in Response to Uropathogenic Escherichia coli Is Part of a Defense Strategy Triggered by the Major Bacterial Flagellar Filament FliC and Contingent on TLR5.

Authors:  Dhruba Acharya; Matthew J Sullivan; Benjamin L Duell; Kelvin G K Goh; Lahiru Katupitiya; Dean Gosling; Michelle N Chamoun; Asha Kakkanat; Debasish Chattopadhyay; Michael Crowley; David K Crossman; Mark A Schembri; Glen C Ulett
Journal:  mSphere       Date:  2019-11-27       Impact factor: 4.389

7.  Mucosal immunization with iron receptor antigens protects against urinary tract infection.

Authors:  Christopher J Alteri; Erin C Hagan; Kelsey E Sivick; Sara N Smith; Harry L T Mobley
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.